Maxi Investments CY Ltd Acquires New Shares in Replimune Group, Inc. $REPL

Maxi Investments CY Ltd bought a new position in Replimune Group, Inc. (NASDAQ:REPL) in the third quarter, HoldingsChannel reports. The fund bought 42,000 shares of the company’s stock, valued at approximately $556,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REPL. Opaleye Management Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter valued at $15,332,000. WINTON GROUP Ltd acquired a new position in shares of Replimune Group in the second quarter worth $115,000. Engineers Gate Manager LP increased its stake in shares of Replimune Group by 15.0% in the second quarter. Engineers Gate Manager LP now owns 172,998 shares of the company’s stock worth $1,915,000 after acquiring an additional 22,504 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Replimune Group in the second quarter worth $151,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Replimune Group in the second quarter worth $1,454,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 8.8%

Shares of REPL opened at $12.47 on Tuesday. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $16.33. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -3.96 and a beta of 0.93. The stock’s 50-day moving average price is $13.48 and its 200 day moving average price is $9.19.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, research analysts predict that Replimune Group, Inc. will post -2.82 earnings per share for the current year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares in the company, valued at $3,082,366.56. This trade represents a 4.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock worth $1,038,364 over the last quarter. 5.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on REPL shares. Wolfe Research raised Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Friday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.